-
NEJM: Brentuximab Vedotin treats high-risk Hodgkin lymphoma in children and adolescents with event-free 3-year survival rate of up to 92%
Time of Update: 2022-11-14
In an ECHELON-1 study involving patients with previously untreated stage III or IV Hodgkin lymphoma, treatment with antibody-drug conjugates targeting CD30, brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AVD) resulted in a mortality risk significantly lower than those observed with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) regimens 。 At 6 years of follow-up, this result translated into an overall difference in mortality of 4.
-
Cancer Chemother Pharmacol: Analysis of exposure response of camimedan mab tercillin in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma
Time of Update: 2022-11-14
Cmaxss is a steady-state maximum serum concentration at cycle 6Figure 3: The effect of model prediction of Cami Cmaxss status on the estimated overall survival probability of cHL patients at cycle 6.
-
Scientific Reports: T cell count in peripheral blood for leukapheresis predicts response to subsequent CAR-T cell therapy
Time of Update: 2022-11-14
In addition, higher CD3+ cell counts during leukapheresis were associated with significantly higher peripheral blood lymphocyte counts on day 7 post-CAR-T cell infusion (median 860 vs 420/μL, P = 0.
-
Isr Med Assoc J: Primary central nervous system lymphoma: clinical features, treatment options and treatment outcomes in 36 patients
Time of Update: 2022-11-14
Treatment of older patients is limited because high-dose chemotherapy combined with autologous transplantation is too toxic for these patients, whereas WBRT has harmful effects and affects survival due to neurotoxic effects.
-
Haemophilia: amizumab dose can be increased in patients with haemophilia A with suboptimal bleeding control
Time of Update: 2022-11-14
The article in this report mainly studies the effect of emilizumab dose increase on poor bleeding control of PwHA.
The article in this report mainly studies the effect of emilizumab dose increase on poor bleeding control of PwHA.
-
A frightening case of blood typing results
Time of Update: 2022-11-14
PreambleCorrect identification of ABO blood group system is the primary prerequisite to ensure the safety of clinical blood transfusion, and it is also the most important blood group system in safe bl
-
Turk J Pediatr； Decreased antioxidant capacity of serum natural thiol and total thiol levels in children with hemophilia A: a prospective case-control study
Time of Update: 2022-11-14
The study reported in this report aimed to determine whether serum levels of native mercaptans, total mercaptans, and disulfides in children with hemophilia A and the ratios between these variables changed compared to normal healthy controls.
-
J Clin Med: Clot waveform analysis of thrombin time with a small amount of thrombin helps assess plasma clotting activity independent of imizumab
Time of Update: 2022-11-14
5 IU/mL) reflects thrombin bursts and can be used to assess FVIII activity, it is independent of the presence of imizumab and can be used to monitor coagulation activity in patients with anti-FVIII inhibitors receiving imizumab Original source:Wada H, Shiraki K, Matsumoto T, Suzuki K, Yamashita Y, Tawara I, Shimpo H, Shimaoka M.
-
Monoclonal immunoglobulin is elevated, don't just think of MM
Time of Update: 2022-11-14
Bone marrow was sent for examination, hyperplasia was active, the proportion of mature lymphocytes increased significantly, accounting for 77%, the three lines were reduced, and the mature red blood cells were arranged in a money-like manner:Flow cytometry showed 71.
-
If the monocyte count is 0, can this result be reviewed?
Time of Update: 2022-11-14
Monocytes are the largest leukocytes in peripheral blood and are the main component of phagocytes in peripheral blood. The reference range of normal adult peripheral blood mononuclear cell count is (0
-
CAR-T therapy targeting BCMA still has good efficacy and safety in RRMM patients who have been exposed to drugs targeting BCMA
Time of Update: 2022-11-05
B cell maturation antigen (BCMA) is mainly expressed on the surface of plasma cells and is a promising target for the treatment of multiple myeloma (MM). Several therapies currently being investigated
-
Big coffee commented on the cutting-edge stripping the cocoon: the diagnosis and treatment of a case of hereditary anemia in a young child
Time of Update: 2022-11-05
weavehe whopressAnemia is a common hematologic symptom in childhood, especially in infancy. The symptoms of pediatric anemia are related to the cause, degree of anemia, rate of occurrence, age of onse
-
Move forward in a collision of ideas! Discovery Super "G" Detective National Finals Ended Successfully - A Wonderful Review of Lymphoma Cases
Time of Update: 2022-11-05
Three exciting cases that take you to the Discovery Super "G" Detective National Finals!In order to deeply explore the real-world drug experience of lymphoma, the Discovery Super "G" Detective Project
-
Express Potential first! The Novartis complement inhibitor phase 3 trial met the primary endpoint
Time of Update: 2022-11-05
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorNovartis recently announced that its new drug iptacopan has achieved positive results in a phase 3 clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), and the hemoglobin level of patients has continued to increase significantly after treatment.
-
Cancer Cell Weng Zhenyou/Chen Jianjun/Huang Huilin/Wei Minjie collaborated to reveal the regulatory mechanism of the m⁶A code reader IGF2BP2 in acute myeloid leukemia
Time of Update: 2022-11-05
On October 27, 2022, Professor Weng Zhenyou of Guangzhou Laboratory, Professor Chen Jianjun of City of Hope, Huang Huilin, researcher of Sun Yat-sen University Cancer Prevention and Treatment Center, and Professor Wei Minjie of China Medical University jointly published an online publication in Cancer Cell magazine entitled " The m6A Reader IGF2BP2 Regulates Glutamine Metabolism and Represents a Therapeutic Target in Acute Myeloid Leukemia", which reports on the carcinogenic effects and therapeutic targeting of IGF2BP2 in AML.
-
Safety and efficacy of Elotuzumab in combination with carfilzomib, lenalidomide and dexamethasone in the treatment of newly diagnosed multiple myeloma
Time of Update: 2022-11-05
Dexamethasone: 40 mg orally weekly (20 mg if age≥ 75 years)The primary endpoint was sCR and/or MRD negativity after eight cycles of Elo-KRd treatment (NGS, 10−5).
Dexamethasone: 40 mg orally weekly (20 mg if age≥ 75 years)The primary endpoint was sCR and/or MRD negativity after eight cycles of Elo-KRd treatment (NGS, 10−5).
-
Chinese hemophilia patients are safely undergone major surgery NEJM after gene therapy
Time of Update: 2022-11-05
-Padua gene therapy, underwent knee replacement for the next 16 months, did not receive any exogenous coagulation factor IX preparation replacement therapy during the perioperative period, did not suffer a large amount of blood loss, and reached a normal hemostatic level.
-
FDA update | approval of teclistamab-cqyv for the treatment of relapsed or refractory multiple myeloma
Time of Update: 2022-11-05
On October 25, 2022, the US Food and Drug Administration (FDA) accelerated the approval of the B cell maturation antigen (BCMA)/CD3 bispecific T cell adaptor teclistamab-cqyv for adult patients with relapsed or refractory multiple myeloma who have received at least four prior fourth-line therapies, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies.
-
Frontier Nature: The most comprehensive map of acute myeloid leukemia to date was born, revealing a new pathogenesis
Time of Update: 2022-11-05
▎WuXi AppTec content team editor Acute myeloid leukemia (AML) is a common type of leukemia that can occur in both children and adults. This malignancy results from differentiation blockade and clonal
-
From repeated bleeding in joints to riding a horse, Chinese hemophilia patients have realized their dreams of grasslands due to gene therapy
Time of Update: 2022-11-05
Physician News (Rong Media reporter Guan Yanqing) began with repeated elbow and knee bleeding at the age of 5, 28-year-old severe hemophilia B patient, Mongolian guy Muge (pseudonym) After more than 2
